Stephen Barter, MD
Family Medicine · Naples, MENPI 1689779092
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 364 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by Novo Nordisk at 26.5% of the total. Among family medicine clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 364 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$999
- Pfizer$621
- GSK$555
- AstraZeneca$416
- Johnson & Johnson$301
- plus $2K from 20 others
What the payments were for
- Food & beverage$6,176100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 92 | $1,638 |
| AbbVie(2 entities) | 62 | $999 |
| Pfizer | 63 | $621 |
| GSK | 31 | $555 |
| AstraZeneca | 22 | $416 |
| Johnson & Johnson | 10 | $301 |
| Lilly USA, LLC | 15 | $260 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $236 |
| Abbott | 8 | $177 |
| Phathom Pharmaceuticals, Inc. | 7 | $177 |
| Merck | 9 | $153 |
| Boehringer Ingelheim | 5 | $103 |
| Teva Pharmaceuticals USA, Inc. | 4 | $74 |
| Axsome Therapeutics, Inc. | 2 | $63 |
| Amgen | 2 | $47 |
| Verona Pharma, Inc. | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $41 |
| Collegium Pharmaceutical, Inc. | 2 | $39 |
| Bayer | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Dexcom, Inc. | 2 | $34 |
| Eisai Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Corcept Therapeutics | 1 | $25 |
| Corium, LLC | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVOKANA$215
- Ozempic$125
- TRELEGY ELLIPTA$125
- RYBELSUS$116
How this compares
$6,176 in reported general payments places this provider in the 95th percentile of 466 family medicine providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 86 | $112,332 |
| XareltoRivaroxaban | 75 | $92,054 |
| OzempicSemaglutide | 53 | $78,153 |
| RybelsusSemaglutide | 26 | $66,759 |
| JardianceEmpagliflozin | 39 | $62,981 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $60,315 |
| CreonLipase/Protease/Amylase | 17 | $49,214 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $39,469 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $36,466 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $25,932 |
| Tresiba Flextouch U-100Insulin Degludec | 34 | $24,390 |
| Spiriva HandihalerTiotropium Bromide | 16 | $15,320 |
| OxycontinOxycodone Hcl | 11 | $13,011 |
| Praluent PenAlirocumab | 11 | $9,906 |
| Emgality PenGalcanezumab-Gnlm | 13 | $8,998 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,638 | $144,91279 claims |
| PfizerEliquis | $621 | $112,33286 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix | $555 | $111,501170 claims |
| Johnson & JohnsonXarelto | $301 | $92,05475 claims |
| Boehringer IngelheimJardiance | $103 | $62,98139 claims |
| AbbVieCreon | $999 | $49,21417 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $416 | $12,37824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family medicine providers in Maine.
Other family medicine in Naples
- Kristy Murray-PulsiferSouth Portland$55K
- Albert HartmanLewiston$33K
- Brian KnightonFreeport$29K
- Edward YoonPortland$27K
- Jennifer FreeseVeazie$19K
- Kohar der SimonianFalmouth$18K
- Jessica Bloom FosterBangor$14K
- Cecily CannonKennebunk$14K
- Maria AtkinsPortland$14K
- Julia McDonaldAugusta$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.